| scholarly article | Q13442814 |
| P50 | author | Charles Erlichman | Q107069384 |
| P2093 | author name string | Paul Haluska | |
| Joan M Carboni | |||
| Marco M Gottardis | |||
| Xiaonan Hou | |||
| Chunrong Yu | |||
| Tai W Wong | |||
| Ricardo M Attar | |||
| Malvika Sagar | |||
| Cynthia TenEyck | |||
| P2860 | cites work | Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. | Q54254361 |
| Circulating concentrations of insulin-like growth factor I and risk of breast cancer | Q57751183 | ||
| Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors | Q73070782 | ||
| Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study | Q73270411 | ||
| Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers | Q78257341 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia | Q79734958 | ||
| Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib | Q80307760 | ||
| Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved | Q24301995 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 | ||
| Cellular actions of the insulin-like growth factor binding proteins | Q28216659 | ||
| Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells | Q28299546 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux | Q32046906 | ||
| Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. | Q33214021 | ||
| Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. | Q33858986 | ||
| hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. | Q34286925 | ||
| Insulin-like growth factors and neoplasia. | Q34330521 | ||
| Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. | Q34578377 | ||
| Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway | Q35024843 | ||
| The therapeutic potential of agents targeting the type I insulin-like growth factor receptor | Q35964712 | ||
| Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | Q36236645 | ||
| IGF-I mediated survival pathways in normal and malignant cells | Q36537634 | ||
| The role of the IGF system in cancer growth and metastasis: overview and recent insights | Q36576678 | ||
| A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer | Q37423291 | ||
| Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib | Q40138493 | ||
| Insulin-like growth factor-I receptor signaling blockade combined with radiation | Q40174217 | ||
| Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase | Q40190634 | ||
| Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism | Q40207997 | ||
| Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. | Q40216149 | ||
| In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. | Q40333087 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity | Q40379343 | ||
| Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. | Q40394719 | ||
| The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway | Q40521524 | ||
| Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system | Q42817129 | ||
| Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product | Q42833317 | ||
| Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling | Q44112871 | ||
| Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells | Q44262979 | ||
| Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells | Q44675816 | ||
| Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors | Q46972238 | ||
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors | Q47860361 | ||
| A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. | Q51518860 | ||
| P433 | issue | 9 | |
| P921 | main subject | preproinsulin | Q7240673 |
| P304 | page(s) | 2589-2598 | |
| P577 | publication date | 2008-09-02 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. | |
| P478 | volume | 7 |
| Q38651792 | A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model |
| Q33406979 | A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors |
| Q33846405 | A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties |
| Q26824462 | A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy |
| Q35146077 | A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity |
| Q39809616 | BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide |
| Q34336988 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? |
| Q24609058 | Cixutumumab |
| Q36357195 | Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? |
| Q37071560 | Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer. |
| Q35592388 | Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft |
| Q37335142 | Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer |
| Q34674256 | Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924 |
| Q37430771 | Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth |
| Q37731144 | Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer |
| Q33979359 | Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse |
| Q42579657 | Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance |
| Q64272147 | EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? |
| Q26863231 | EGFR/HER-targeted therapeutics in ovarian cancer |
| Q34133760 | ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis |
| Q33923364 | Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors |
| Q37565213 | Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). |
| Q30411769 | Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma |
| Q46789988 | Expression and significance of IGF-1 and IGF-1R in thyroid nodules |
| Q38393712 | Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth |
| Q35201923 | HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells |
| Q35494483 | Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors |
| Q37309022 | IGF-1 receptor inhibitors in clinical trials--early lessons |
| Q42322249 | IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin |
| Q37615933 | IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights |
| Q35836632 | IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors |
| Q39314094 | Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. |
| Q36082594 | Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells. |
| Q33921296 | Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. |
| Q38410339 | Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. |
| Q39449572 | Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers |
| Q37773265 | Insulin-like growth factor receptor type I as a target for cancer therapy |
| Q36387216 | Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor |
| Q35989684 | Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing |
| Q28088432 | Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade |
| Q36673960 | Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors |
| Q26764879 | Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab |
| Q39850815 | Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone |
| Q37682761 | Pathogenesis of osteoblastic bone metastases from prostate cancer |
| Q36051560 | Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors |
| Q33395016 | Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma |
| Q36084201 | Quantifying insulin receptor isoform expression in FFPE breast tumors |
| Q36169793 | Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer |
| Q30395770 | Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer |
| Q37859024 | Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer |
| Q39659456 | Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases |
| Q33581021 | Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer |
| Q37975246 | Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy |
| Q38302045 | The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web. |
| Q55220517 | The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. |
| Q27013945 | The insulin-like growth factor system in cancer |
| Q39899686 | The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors |
| Q37304764 | The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer |
| Q34172625 | The proliferating role of insulin and insulin-like growth factors in cancer |
| Q37702186 | Type I insulin-like growth factor receptor signaling in hematological malignancies |
| Q31038305 | Where now for anti-EGF receptor therapies in colorectal cancer? |
| Q37138970 | XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer |
| Q35683561 | erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines |
Search more.